Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 1,001–1,031 of 1,031
Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking
Cheng, S., Zhang, W., Inghirami, G., & Tam, W. (2021) · eLife · doi:10.7554/elife.66395 · Cited by 37
“…cells harboring one or more somatic mutations as a result of selective advantage in the hematopoietic stem and progenitor cells due to enhanced self- renewal and inhibition of differentiation (Challen and Goodell, 2020; Gondek and DeZern, 2020; Jaiswal and Ebert, 2019; Steensma and Ebert, 2020).”
BackgroundRamabadran, R., Wang, J. H., Reyes, J. M., Guzman, A. G., Gupta, S., Rosas, C., Brunetti, L., Gundry, M. C., Tovy, A., Long, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01109-9 · Cited by 35
Ketkar, S., Verdoni, A. M., Smith, A. M., Bangert, C. V., Leight, E. R., Chen, D. Y., Brune, M. K., Helton, N. M., Hoock, M., George, D. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918611117 · Cited by 35
“M utations in the DNMT3A gene are the most common events associated with age-related clonal hematopoiesis (ARCH) (1 – 4), and are among the most common initiating mutations in acute myeloid leukemia (AML) (5 – 7).”
Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments
Ashcroft, P., Manz, M. G., & Bonhoeffer, S. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005803 · Cited by 32
“Clinical studies have shown that 10% of people over 65 years of age display clonality, yet 42% of those developing hematologic cancer displayed clonality prior to diagnosis [13].”
BackgroundDawar, S., Shahrin, N. H., Sladojevic, N., D'Andrea, R. J., Dorstyn, L., Hiwase, D. K., & Kumar, S. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.406 · Cited by 30
Herbrich, S., Chaib, M., Anandhan, S., Andrewes, S. W., Nagarajan, A., Guan, B., Gandhi, N., Gilliam, J., Radovich, M., & Sharma, P. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.09.011 · Cited by 30
Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases
Liu, X., Xue, H., Wirdefeldt, K., Song, H., Smedby, K., Fang, F., & Liu, Q. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20001 · Cited by 29
Liquid biopsy: creating opportunities in brain space
Trivedi, R., & Bhat, K. P. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02446-0 · Cited by 27
An improved epigenetic counter to track mitotic age in normal and precancerous tissues
Zhu, T., Tong, H., Du, Z., Beck, S., & Teschendorff, A. E. (2024) · Nature Communications · doi:10.1038/s41467-024-48649-8 · Cited by 27
Das, A. B., Smith-Díaz, C. C., & Vissers, M. C. M. (2020) · Haematologica · doi:10.3324/haematol.2020.259283 · Cited by 25
Niederwieser, C., Morozova, E., Zubarovskaya, L., Zabelina, T., Klyuchnikov, E., Janson, D., Wolschke, C., Christopeit, M., Ayuk, F., Moiseev, I., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01410-x · Cited by 24
Matatall, K. A., Wathan, T. K., Nguyen, M., Chen, H., McDonald, A., Qi, G., Belk, J. A., Florez, M. A., Le, D. T., Olarinde, T., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.06.006 · Cited by 23
Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21
Zhang, C. R., Ostrander, E. L., Kukhar, O., Mallaney, C., Sun, J., Haussler, E., Celik, H., Koh, W. K., King, K. Y., Gontarz, P., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0132 · Cited by 23
Aivalioti, M. M., Bartholdy, B. A., Pradhan, K., Bhagat, T. D., Zintiridou, A., Jeong, J. J., Thiruthuvanathan, V. J., Pujato, M., Paranjpe, A., Zhang, C., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0226 · Cited by 22
A microglia clonal inflammatory disorder in Alzheimer’s disease
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B., Socci, N. D., Alberdi, A., Baako, A., et al. (2025) · eLife · doi:10.7554/elife.96519.3 · Cited by 21
“TET2, DNMT3, and KMT2C are frequently mutated in clonal hematopoiesis ( Jaiswal et al., 2014 ; Genovese et al., 2014 ), suggesting that in contrast to other variants, the presence of TET2, DNMT3, and KMT2C/MLL3 in the brain of patients may reflect the entry of blood clones in the brain.”
Turkalj, S., Jakobsen, N. A., Groom, A., Metzner, M., Riva, S. G., Gür, E. R., Usukhbayar, B., Salazar, M. A., Hentges, L. D., Mickute, G., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.012 · Cited by 20
Personalized Cancer Risk Assessments for Space Radiation Exposures
Locke, P. A., & Weil, M. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00038 · Cited by 20
“The frequency of people harboring these cells increases with age and is associated with an increased risk of hematopoietic cancer (26, 27).”
BackgroundClone wars: the emergence of neoplastic blood-cell clones with aging
Abkowitz, J. L. (2014) · New England Journal of Medicine · doi:10.1056/nejme1412902 · Cited by 18
Andina, N., de Meuron, L., Schnegg-Kaufmann, A. S., Sarangdhar, M. A., Ansermet, C., Bombaci, G., Batta, K., Keller, N., Porret, N. A., Angelillo-Scherrer, A., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200412 · Cited by 16
Huang, A. Y., Zhou, Z., Talukdar, M., Miller, M. B., Chhouk, B., Enyenihi, L., Rosen, I., Stronge, E., Zhao, B., Kim, D., et al. (2024) · doi:10.1101/2024.01.03.574078 · Cited by 16
Huang, A. Y., Zhou, Z., Talukdar, M., Enyenihi, L., Miller, M. B., Chhouk, B., Rosen, I., Zheng, M., Zhou, M., Yang, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.040 · Cited by 15
“19 Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease, 20,21 likely through inflammatory effects of mutant cells.”
Yang, Y., Cathelin, S., Liu, A. C. H., Subedi, A., Maher, A., Hosseini, M., Manikoth Ayyathan, D., Vanner, R., & Chan, S. M. (2025) · Nature Communications · doi:10.1038/s41467-025-57614-y · Cited by 14
“Loss-of-function (LoF) mutations in TET2 are found in 10 – 30% of CHIP carriers 8 – 10 .”
Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway
Palam, L. R., Ramdas, B., Pickerell, K., Pasupuleti, S. K., Kanumuri, R., Cesarano, A., Szymanski, M., Selman, B., Dave, U. P., Sandusky, G., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163864 · Cited by 13
Proliferation: Driver of HSC aging phenotypes?
Yanai, H., & Beerman, I. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111331 · Cited by 9
“This clonal expansion can occur independently of clinical blood disorders (Cooper and Young, 2017) but is considered a predisposition for them, including associations to hematologic cancers (Genovese et al., 2014; Jaiswal et al., 2014; Shlush et al., 2014; Welch et al., 2012), atherosclerosis (Jaiswal et al.”
BackgroundTargeting Immune Signaling Pathways in Clonal Hematopoiesis
Azrakhsh, N. A., Mensah-glanowska, P., Sand, K., & Kittang, A. O. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190325100636 · Cited by 8
Evolution of Multiple Myeloma from a Genomic Perspective
Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8
Kousi, M., Boix, C., Park, Y. P., Mathys, H., Sledzieski, S., Peng, Z., Bennett, D. A., Tsai, L.-H., & Kellis, M. (2022) · doi:10.1101/2022.04.21.489103 · Cited by 7
Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis
Feng, J., Wu, B., Li, Y., Sun, P., Liu, Q., Xiao, Q., Cai, J.-B., Zheng, Y., Chen, H., Xu, Y., et al. (2026) · Journal of Experimental Medicine · doi:10.1084/jem.20251114 · Cited by 6
“Notably, TET2 mutations in myeloid cells are detected in ∼ 10% of individuals over 65 years old, making CHIP significantly more prevalent in the elderly (Ferrone et al., 2020; Jaiswal and Ebert, 2019; Genovese et al., 2014).”
Clonal Hematopoiesis Mutations Increase Risk of Alzheimer’s Disease with APOE ε3/ε3 Genotype
Choi, J., Park, K. S., Le Guen, Y., Park, J.-H., Zhou, Z., Enyenihi, L., Rosen, I., Choi, Y.-H., Walsh, C. A., Kim, J.-W., et al. (2025) · doi:10.1101/2025.05.19.654981 · Cited by 5
“2D) are all well-established CHIP-107 associated genes 6,8,13,15,17,18 , suggesting that these somatic mutations may confer a proliferative advantage to the cells carrying them, and that AD may create an environment that selects for mutant clones.”
Evans, M. A., Chavkin, N. W., Sano, S., Sun, H., Sardana, T., Ravi, R., Doviak, H., Wang, Y., Yura, Y., Polizio, A. H., et al. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1487867 · Cited by 4
Kopp, K., Silva, P., Damm, F., & Cosma, N. C. (2026) · Biomedicines · doi:10.3390/biomedicines14051012
“Functionally, clonal hematopoiesis-associated mutations alter the behavior of hematopoietic stem cells (HSCs); some also confer a fitness advantage, leading to clonal expansion [27,28].”
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.